Breast Cancer Care and Breast Cancer Now responds to the National Audit of Breast Cancer in Older Patients 2019 Annual Report

The National Audit of Breast Cancer in Older Patients (NABCOP), carried out by the Royal College of Surgeons and the Association of Breast Surgery,...

10 May 2019

We respond to study suggesting foods containing phenolic acids may help lower breast cancer risk

New research presented at the European Congress on Obesity has suggested that nutrients called phenolic acids – which are found in foods such as...

2 May 2019

We respond to cancer incidence in Scotland

Breast Cancer Care and Breast Cancer Now respond to a report on cancer incidence in Scotland.  Ashleigh Simpson, Policy and Campaigns...

1 May 2019

We respond to NHS Tayside Clinical Risk Assessment Report

The Clinical Risk Assessment report follows a previous report from Health Improvement Scotland which highlighted that patients in NHS Tayside...

17 April 2019

We respond to NICE draft decision to reject ribociclib with fulvestrant for use on the NHS

The National Institute for Health and Care Excellence (NICE) has today (10 April 2019) provisionally rejected breast cancer drug ribociclib in...

10 April 2019

We respond to report on clinical management of breast cancer in NHS Tayside

Health Improvement Scotland has issued a report into the clinical management of breast cancer in NHS Tayside which highlights local inconsistencies...

5 April 2019

We respond to NICE approval of abemaciclib with fulvestrant for use on the Cancer Drugs Fund

The National Institute for Health and Care Excellence (NICE) has today published draft guidance recommending breast cancer drug abemaciclib with...

2 April 2019

We respond to new analysis predicting UK breast cancer mortality rates are to improve in 2019

Mortality rates from breast cancer are predicted to fall in the UK and across Europe (except for in Poland) by 2019, according to new research...

19 March 2019

We respond to news that immunotherapy atezolizumab is to be made temporarily available to certain NHS breast cancer patients via early access scheme

New breast cancer immunotherapy atezolizumab (Tecentriq) is to be made available in the short term for certain NHS patients with metastatic ‘triple...

15 March 2019